أخبار الشركة

من 16 إلى 18 يونيو، اختتم الحدث الصناعي الرابع والعشرون للمكونات الدوائية العالمية في الصين (CPHI China 2026)، وهو حدث صناعي استمر ثلاثة أيام، بنجاح كبير في مركز شنغهاي الدولي الجديد للمعرض الصناعي. في هذا التجمع الكبير ل

Recently, BONTAC Biotech has made frequent appearances on the international stage. Following its successful participation in Hi Japan in Tokyo, the company once again shined at two major global events — CPHI F

From October 15 to 17, the HI Japan 2025 Health Ingredients Exhibition was grandly held in Tokyo. As a pioneer in the NMN industry and a globally leading biotechnology company, Bontac was invited to participate, s

On October 20, 2025, the Shenzhen SME Service Bureau announced the list of the seventh batch of "Little Giant" enterprises and the 2025 re-evaluated enterprises. Bontac, with its outstanding comprehensive stre

On August 5, Bontac NR Hydrogen Malate product successfully obtained a patent certificate issued by the United States Patent and Trademark Office (USPTO) (Publication No.: US12378279B2), marking another authoritativ

June 24-26 , the 23rd China International Pharmaceutical Ingredients Exhibition （ CPHI China 2025 ）The Shanghai New International Expo Center （Pudong） grand opening. Bontac, as one of the exhibit

في معرض الأغذية الصحية المرموق والمكونات والتصنيع التعاقدي لعام 2025 الذي أقيم في منتدى طوكيو الدولي، جذبت بونتاك اهتماما عالميا من خلال عرضها ابتكاراتها الرائدة في مكملات NAD⁺ الكاملة. مع ove

Recently, China National Intellectual Property Administration officially granted Bontac Bioengineering (Shenzhen) Co., Ltd. a significant invention patent—“Amorphous Compound of Reduced β-Nicotinamide Mo

  Introduction On July 26th, 2024, BONTAC, together with Shenzhen Health Industry Development Promotion Association, successfully held the 60th Vice President Salon of Shenzhen Health Industry with the theme